Joseph Feczko Net Worth

The estimated Net Worth of Joseph M Feczko is at least $7.95 Milion dollars as of 21 January 2022. Joseph Feczko owns over 37,500 units of ChemoCentryx Inc stock worth over $7,701,123 and over the last 13 years he sold CCXI stock worth over $0. In addition, he makes $253,708 as Independent Director at ChemoCentryx Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Joseph Feczko CCXI stock SEC Form 4 insiders trading

Joseph has made over 5 trades of the ChemoCentryx Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 37,500 units of CCXI stock worth $577,875 on 21 January 2022.

The largest trade he's ever made was exercising 37,500 units of ChemoCentryx Inc stock on 21 January 2022 worth over $577,875. On average, Joseph trades about 6,668 units every 191 days since 2012. As of 21 January 2022 he still owns at least 148,127 units of ChemoCentryx Inc stock.

You can see the complete history of Joseph Feczko stock trades at the bottom of the page.

Joseph Feczko biography

Dr. Joseph M. Feczko M.D. serves as Independent Director of the Company. Until his retirement in May 2009, Dr. Feczko was Senior Vice President and Chief Medical Officer of Pfizer Inc. and a member of its Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.S. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko presently serves on the board of directors of Adenium Biotech. Feczko is qualified to serve on our board of directors because of his international leadership and management experience from his service as the Chief Medical Officer of a public pharmaceutical company and as a director of several pharmaceutical and biotechnology companies.

What is the salary of Joseph Feczko?

As the Independent Director of ChemoCentryx Inc, the total compensation of Joseph Feczko at ChemoCentryx Inc is $253,708. There are 10 executives at ChemoCentryx Inc getting paid more, with Thomas Schall having the highest compensation of $3,341,860.

How old is Joseph Feczko?

Joseph Feczko is 71, he's been the Independent Director of ChemoCentryx Inc since 2012. There are 1 older and 12 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.

What's Joseph Feczko's mailing address?

Joseph's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 835 INDUSTRIAL ROAD, SUITE 600, SAN CARLOS, CA, 94070.

Insiders trading at ChemoCentryx Inc

Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta oraz (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.

What does ChemoCentryx Inc do?

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Complete history of Joseph Feczko stock trades at ChemoCentryx Inc

ChemoCentryx Inc executives and stock owners

ChemoCentryx Inc executives and other stock owners filed with the SEC include:

• Thomas Schall,
  Chairman of the Board, President, Chief Executive Officer
• Susan Kanaya,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary
• Markus Cappel,
  Chief Business Officer, Treasurer
• Dr. Thomas J. Schall Ph.D.,
  Founder, Pres, CEO & Chairman
• Susan M. Kanaya,
  Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
• Dr. Markus J. Cappel Ph.D.,
  Sr. VP, Chief Bus. Officer & Treasurer
• Rita Jain,
  Independent Director
• James Tyree,
  Independent Director
• Henry McKinnell,
  Independent Director
• Thomas Edwards,
  Independent Director
• Joseph Feczko,
  Independent Director
• Geoffrey Parker,
  Independent Director
• Dr. Rita I. Jain M.D.,
  Exec. VP, Chief Medical Officer & Exec. Employee Director
• Dr. Sangita Ghosh Ph.D.,
  Sr. VP of Technical Operations
• Dalia R. Rayes,
  Sr. VP & Head of Commercial
• Kari E. Leetch,
  Sr. VP of HR
• Tausif Butt,
  Exec. VP & COO
• Roger C Lucas,
  Director
• Petrus Bekker,
  SVP of Medical & Clinical
• Rajinder Singh,
  SVP, Research
• Partners L P/Ilbiotechnolog...,
  
• Jennifer Lyn Herron,
  Director
• Pui San Kwan,
  Principal Acctg Officer
• William Fairey,
  Chief Operating Officer
• Plc Gsk,
  10% owner
• Edward Penhoet,
  Director
• Ira Klein,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Anne Marie Duliege,
  EVP, Chief of Strategic Dev.
• Israel Charo,
  SVP, Research
• Juan C. Jaen,
  SVP, Drug Discovery & CSO
• Tausif Butt,
  EVP, Chief Operating Officer
• Partners L P/Ilbvf Investme...,
  
• Corp /Mn/ Techne,
  10% owner
• Advisors Llcorbimed Capital...,
  
• Rishi Gupta,
  Director
• (International) Ltd Vifor P...,
  
• Yi Ching Yau,
  SVP, Finance & Acctg Officer
• David E. Wheadon,
  Director